In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing regimen. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will probably be offered as "insert-on" therapy. In https://abbv-744-brd4-inhibition79124.webbuzzfeed.com/32570042/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml